Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Prevalence and severity of fatigue in castration resistant prostate cancer in Spain: VITAL study

Date

09 Oct 2016

Session

Poster display

Presenters

Luis Martínez-Piñeiro

Citation

Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372

Authors

L. Martínez-Piñeiro1, A. Rodríguez Antolín2, M.E. Jiménez Romero3, J.B. García Ramos4, D. Lopez Bellido5, P. Ruiz Gracia6, A. Garcia Garcia-Porrero7, F. Gomez Veiga8

Author affiliations

  • 1 Urology, Hospital Infanta Sofia, 28703 - Madrid/ES
  • 2 Urology, University Hospital 12 De Octubre, Madrid/ES
  • 3 Urology, Hospital Universitario de Puerto Real, Cadiz/ES
  • 4 Urology, Complejo Hospitalario de Huelva, Huelva/ES
  • 5 Urology, Complejo Hospitalario Universitario de Orense, Ourense/ES
  • 6 Maf Departement Oncology, Janssen Cilag, Spain, Madrid/ES
  • 7 Oncology, Janssen Cilag, Spain, Madrid/ES
  • 8 Urology, Hospital Universitario de Salamanca, Salamanca/ES
More

Resources

Abstract 1956

Background

Fatigue is the most common and distressing symptom of which castration resistant prostate cancer (CRPC) patients complain. The little evidence of fatigue prevalence, intensity and interference with daily activities in advanced prostate cancer that exists is mainly restricted to post-docetaxel setting with Abiraterone Acetate (AA). The VITAL study examines the prevalence and intensity of cancer-related fatigue (CRF) in CRPC.

Methods

cross-sectional study of CRPC patients including chemo-naïve metastatic (mCRPC) or high risk M0CRPC (PSADT ≤ 10mo) in routine clinical practice. Fatigue and Quality of Life (QoL) data were collected using validated patient self-reported questionnaires(BFI-SF and FACT-G/P). Fatigue correlation with both patient's and physiciańs perception was assessed.

Results

235 patients were recruited (Jan-Sept 2015). Median age: 75.1 (46.2-92.4), median PSA: 17.8 ng/ml (0-2000), metastatic disease: 68.5%, ECOG 0-1: 90.6%. There was a high prevalence of fatigue (M1:73.9%; M0: 74.3%), with 38.3% of the patients having moderate or severe fatigue. High concordance existed between fatigue physiciańs and patient's perception (Kappa index: 0.818). Cardiovascular and respiratory disorders were associated with an increase of fatigue in the multivariate analysis (OR: 4.7 and 3.6 respectively, p 

Conclusions

Our data show a high prevalence and intensity of fatigue and impact in QoL in chemo-naïve CRPC patients. The study highlights the relevance of fatigue awareness and its management in CRPC patients. Table.

FACT-G total score FACT-P total score
FATIGUE Mean SD N Mean SD N
Abscence 88.0 13.3 60 127.7 16.9 60
Mildly 79.3 12.9 84 110.1 16.3 84
Moderate 71.5 14.7 64 110.8 19.3 64
Severe 63.2 19.2 25 87.7 25.1 25
p-valor*

Clinical trial identification

Legal entity responsible for the study

Jannsen-Cilag, Spain

Funding

Janssen-Cilag, Spain

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.